

D K-H Wong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9576162/publications.pdf>

Version: 2024-02-01

159
papers

8,620
citations

34076

52
h-index

51562

86
g-index

161
all docs

161
docs citations

161
times ranked

6410
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Antiviral Treatment on Hepatitis B Virus Integration and Hepatocyte Clonal Expansion. <i>Clinical Infectious Diseases</i> , 2023, 76, e801-e809.	2.9	13
2	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2022, 71, 789-797.	6.1	25
3	Phenotypic Changes of PD-1 and GITR in T Cells Are Associated With Hepatitis B Surface Antigen Seroclearance. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e31-e37.	1.1	4
4	Stanniocalcin 1 is a serum biomarker and potential therapeutic target for HBV-associated liver fibrosis. <i>Journal of Pathology</i> , 2022, , .	2.1	10
5	Patient plgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 883-895.	1.8	32
6	Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction. <i>Frontiers in Microbiology</i> , 2022, 13, 813783.	1.5	6
7	Detection of the Hepatitis B Surface Antigen in Patients with Occult Hepatitis B by Use of an Assay with Enhanced Sensitivity. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0220421.	1.8	8
8	Hepatitis B virus X protein promotes hepatocarcinogenesis via the activation of HMGA2/STC2 signaling to counteract oxidative stress-induced cell death. <i>Carcinogenesis</i> , 2022, 43, 671-681.	1.3	5
9	Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5127-5136.	1.1	3
10	Enhanced Liver Fibrosis Score Stratifies Hepatocellular Carcinoma Risk in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical Infectious Diseases</i> , 2022, 75, 2257-2259.	2.9	1
11	Sparse logistic regression revealed the associations between HBV PreS quasispecies and hepatocellular carcinoma. <i>Virology Journal</i> , 2022, 19, .	1.4	1
12	HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2167-2179.	3.6	50
13	Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. <i>Gut</i> , 2021, 70, 775-783.	6.1	50
14	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 408-409.	2.4	0
15	Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. <i>Journal of Gastroenterology</i> , 2021, 56, 479-488.	2.3	31
16	First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. <i>BMC Gastroenterology</i> , 2021, 21, 123.	0.8	11
17	Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma. <i>Cell Death Discovery</i> , 2021, 7, 88.	2.0	15
18	Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. <i>Hepatology International</i> , 2021, 15, 901-911.	1.9	24

#	ARTICLE	IF	CITATIONS
19	Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 449-456.	2.4	47
20	Nidogen 1â€Enriched Extracellular Vesicles Facilitate Extrahepatic Metastasis of Liver Cancer by Activating Pulmonary Fibroblasts to Secrete Tumor Necrosis Factor Receptor 1. <i>Advanced Science</i> , 2020, 7, 2002157.	5.6	50
21	Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment. <i>Journal of Hepatology</i> , 2020, 73, S20.	1.8	30
22	Plasma adipocyte fatty acid-binding protein and adiponectin levels are associated with fibrosis regression in nucleoside analogue-treated chronic hepatitis B: a prospective study with paired transient elastography. <i>Journal of Hepatology</i> , 2020, 73, S587-S588.	1.8	0
23	Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance. <i>Journal of Hepatology</i> , 2020, 73, 952-964.	1.8	115
24	Rebound of HBV DNA after cessation of nucleos(t)ide analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA. <i>JHEP Reports</i> , 2020, 2, 100112.	2.6	29
25	Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 800-806.	1.8	82
26	HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. <i>Scientific Reports</i> , 2020, 10, 802.	1.6	18
27	Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2020, 14, 665-668.	1.4	6
28	Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 789.	1.1	12
29	Hepatitis B coreâ€related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1473-1480.	1.0	22
30	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3630-3641.	1.1	1
31	Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 423.	3.5	47
32	A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. <i>Journal of Infectious Diseases</i> , 2019, 219, 1924-1933.	1.9	32
33	Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. <i>Hepatology International</i> , 2019, 13, 148-156.	1.9	12
34	Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2019, 220, 940-950.	1.9	3
35	Fibrosis evolution in chronic hepatitis B e antigenâ€negative patients across a 10â€year interval. <i>Journal of Viral Hepatitis</i> , 2019, 26, 818-827.	1.0	40
36	Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on longâ€term nucleoside analogue. <i>Liver International</i> , 2019, 39, 1217-1225.	1.9	11

#	ARTICLE	IF	CITATIONS
37	Serum Mac-2 binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1817-1823.	1.4	12
38	Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1410-1412.	2.4	7
39	Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2019, 25, 1398-1408.	1.4	14
40	Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e antigen seroclearance. <i>Hepatology</i> , 2018, 68, 462-472.	3.6	48
41	Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 575-583.e2.	2.4	86
42	Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 43-54.	1.9	161
43	Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 97-104.	1.0	84
44	Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e163.	1.3	26
45	Quantitative hepatitis B surface antigen in predicting recurrence of hepatitis B-related hepatocellular carcinoma after liver transplantation. <i>Hepatoma Research</i> , 2018, 4, 62.	0.6	4
46	The role of interleukin-27 in predicting spontaneous HBsAg seroconversion in chronic hepatitis B infection. <i>Liver International</i> , 2017, 37, 1287-1294.	1.9	5
47	Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2017, 1860, 491-501.	0.9	47
48	Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. <i>Journal of Viral Hepatitis</i> , 2017, 24, 654-661.	1.0	62
49	Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. <i>Antiviral Research</i> , 2017, 144, 1-7.	1.9	54
50	Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2017, 52, 1064-1074.	2.3	14
51	Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. <i>Hepatology</i> , 2017, 65, 1451-1461.	3.6	81
52	Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. <i>Liver International</i> , 2017, 37, 995-1001.	1.9	132
53	Hepatitis B core protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 1153-1159.	1.5	34
54	Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, 275-281.	1.8	126

#	ARTICLE	IF	CITATIONS
55	Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. <i>Oncotarget</i> , 2017, 8, 47507-47517.	0.8	29
56	Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0148493.	1.1	19
57	Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. <i>Liver International</i> , 2016, 36, 642-650.	1.9	9
58	Hepatitis B virus full-length genomic mutations and quasispecies in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1638-1645.	1.4	10
59	Interleukin-1 β increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model. <i>Oncology Letters</i> , 2016, 11, 2919-2924.	0.8	26
60	Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. <i>American Journal of Gastroenterology</i> , 2016, 111, 1788-1795.	0.2	58
61	Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection. <i>Clinical Microbiology and Infection</i> , 2016, 22, 290.e1-290.e3.	2.8	9
62	Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. <i>Journal of Gastroenterology</i> , 2016, 51, 487-495.	2.3	28
63	Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. <i>Oncotarget</i> , 2015, 6, 34941-34952.	0.8	52
64	Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0139478.	1.1	13
65	Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study. <i>Liver International</i> , 2015, 35, 854-859.	1.9	6
66	Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection. <i>PLoS ONE</i> , 2014, 9, e99028.	1.1	15
67	Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3736-3743.	0.8	283
68	HLA-DP and β 2-microglobulin gene variants and their association with viral hepatitis activity in chronic hepatitis B infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 533-539.	1.4	4
69	Hepatitis B Surface Antigen Seroclearance: Relationship to Hepatitis B e-Antigen Seroclearance and Hepatitis B e-Antigen-Negative Hepatitis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1764-1770.	0.2	19
70	Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. <i>Clinical Microbiology and Infection</i> , 2014, 20, 1173-1180.	2.8	110
71	Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. <i>Molecular Biology Reports</i> , 2014, 41, 2989-2997.	1.0	58
72	Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries. <i>Molecular Biology Reports</i> , 2014, 41, 4713-4720.	1.0	9

#	ARTICLE	IF	CITATIONS
73	Application of Coamplification at Lower Denaturation Temperature-PCR Sequencing for Early Detection of Antiviral Drug Resistance Mutations of Hepatitis B Virus. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3209-3215.	1.8	12
74	Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1028-1034.	1.4	58
75	Effect of Hepatitis B Virus Reverse Transcriptase Variations on Entecavir Treatment Response. <i>Journal of Infectious Diseases</i> , 2014, 210, 701-707.	1.9	10
76	Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance. <i>PLoS ONE</i> , 2014, 9, e99422.	1.1	9
77	Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. <i>Hepatology International</i> , 2013, 7, 98-105.	1.9	34
78	Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. <i>Hepatology International</i> , 2013, 7, 119-126.	1.9	11
79	Characterization of interleukin-1 β in Helicobacter pylori-induced gastric inflammation and DNA methylation in interleukin-1 receptor type 1 knockout (IL-1R1 $^{-/-}$) mice. <i>European Journal of Cancer</i> , 2013, 49, 2760-2770.	1.3	46
80	Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 470-477.	1.0	24
81	Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. <i>Hepatology</i> , 2013, 58, 923-931.	3.6	88
82	Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1004-1010.e1.	2.4	122
83	Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. <i>Journal of Hepatology</i> , 2013, 59, 709-716.	1.8	52
84	Reply to Liao et al. <i>Clinical Infectious Diseases</i> , 2013, 57, 622-622.	2.9	1
85	HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2013, 56, 1695-1703.	2.9	58
86	Defining Normal Liver Stiffness Range in a Normal Healthy Chinese Population without Liver Disease. <i>PLoS ONE</i> , 2013, 8, e85067.	1.1	38
87	Role of HLA-DP Polymorphisms on Chronicity and Disease Activity of Hepatitis B Infection in Southern Chinese. <i>PLoS ONE</i> , 2013, 8, e66920.	1.1	42
88	Outcome of Lamivudine-Resistant Chronic Hepatitis B after up to 5 Years of Combination Therapy with Adefovir. <i>Antiviral Therapy</i> , 2012, 17, 1255-1262.	0.6	18
89	A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e32622.	1.1	65
90	High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e43087.	1.1	71

#	ARTICLE	IF	CITATIONS
91	A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. <i>Hepatology</i> , 2012, 56, 812-819.	3.6	82
92	<i>Helicobacter pylori</i> induces promoter methylation of E-cadherin via interleukin-1 β activation of nitric oxide production in gastric cancer cells. <i>Cancer</i> , 2012, 118, 4969-4980.	2.0	93
93	Transmissibility of Hepatitis B Virus (HBV) Infection through Blood Transfusion from Blood Donors with Occult HBV Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 624-632.	2.9	83
94	Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy. <i>Journal of Hepatology</i> , 2011, 54, 195-200.	1.8	29
95	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. <i>Journal of Hepatology</i> , 2011, 55, 522-528.	1.8	33
96	Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, 738-744.	1.0	42
97	Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. <i>Journal of Viral Hepatitis</i> , 2011, 18, e200-5.	1.0	47
98	Stability of hepatitis B surface antigen over time: Implications for studies using stored sera. <i>Journal of Medical Virology</i> , 2011, 83, 1900-1904.	2.5	7
99	Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years. <i>Hepatology</i> , 2011, 53, 1148-1153.	3.6	12
100	Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. <i>Hepatology</i> , 2011, 54, 829-836.	3.6	135
101	Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1264-1271.	0.2	145
102	Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment. <i>American Journal of Gastroenterology</i> , 2011, 106, 1766-1773.	0.2	62
103	Mild-to-Moderate Elevation of Alanine Aminotransferase Increases Liver Stiffness Measurement by Transient Elastography in Patients With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2011, 106, 492-496.	0.2	52
104	The hepatitis B virus-associated estrogen receptor alpha (ER α) was regulated by microRNA-130a in HepG2.2.15 human hepatocellular carcinoma cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2011, 43, 640-646.	0.9	13
105	Association of Hepatitis B Virus Pre-S Deletions with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2011, 203, 646-654.	1.9	82
106	A New Model Using Routinely Available Clinical Parameters to Predict Significant Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2011, 6, e23077.	1.1	69
107	Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. <i>Hepatology International</i> , 2010, 4, 716-722.	1.9	29
108	Profile of pre-S deletions in the natural history of chronic hepatitis B infection. <i>Journal of Medical Virology</i> , 2010, 82, 1843-1849.	2.5	12

#	ARTICLE	IF	CITATIONS
109	Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. <i>Gut</i> , 2010, 59, 1389-1393.	6.1	65
110	Correlation of Liver Stiffness and Histological Features in Healthy Persons and in Patients With Occult Hepatitis B, Chronic Active Hepatitis B, or Hepatitis B Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1116-1122.	0.2	52
111	Natural history of chronic hepatitis C: Genotype 1 versus genotype 6. <i>Journal of Hepatology</i> , 2010, 53, 444-448.	1.8	35
112	The Duration of Lamivudine Therapy for Chronic Hepatitis B: Cessation vs. Continuation of Treatment After HBeAg Seroconversion. <i>American Journal of Gastroenterology</i> , 2009, 104, 1940-1946.	0.2	68
113	Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. <i>Journal of Hepatology</i> , 2009, 50, 80-88.	1.8	517
114	Prevention and management of drug resistance for antihepatitis B treatment. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 256-264.	4.6	36
115	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. <i>Antiviral Therapy</i> , 2009, 14, 679-685.	0.6	9
116	Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. <i>Liver International</i> , 2008, 28, 1408-1416.	1.9	77
117	HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1192-1199.	0.6	370
118	Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report. <i>Vaccine</i> , 2008, 26, 6587-6591.	1.7	74
119	Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. <i>Gut</i> , 2007, 57, 98-102.	6.1	154
120	Hepatitis B Virus Core-Related Antigens as Markers for Monitoring Chronic Hepatitis B Infection. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3942-3947.	1.8	139
121	Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. <i>Hepatology</i> , 2007, 46, 1695-1703.	3.6	111
122	Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. <i>Journal of Viral Hepatitis</i> , 2007, 14, 269-275.	1.0	36
123	Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 377-382.	1.9	34
124	Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. <i>Journal of Infection</i> , 2007, 54, 497-503.	1.7	12
125	Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. <i>Antiviral Therapy</i> , 2007, 12, 1295-303.	0.6	78
126	Adefovir Dipivoxil Monotherapy and Combination Therapy with Lamivudine for the Treatment of Chronic Hepatitis B in an Asian Population. <i>Antiviral Therapy</i> , 2007, 12, 41-46.	0.6	40

#	ARTICLE	IF	CITATIONS
127	Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease. <i>Antiviral Therapy</i> , 2007, 12, 1295-1304.	0.6	230
128	Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006, 45, 553-559.	1.8	84
129	Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1179-1186.	1.9	103
130	One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. <i>Antiviral Therapy</i> , 2006, 11, 909-16.	0.6	32
131	Significance of Viral Load, Core Promoter/Precore Mutations and Specific Sequences of Polymerase Gene in Hbv-Infected Patients on 3-Year Lamivudine Treatment. <i>Antiviral Therapy</i> , 2006, 11, 779-786.	0.6	21
132	One-Year Entecavir or Lamivudine Therapy Results in Reduction of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA Levels. <i>Antiviral Therapy</i> , 2006, 11, 909-916.	0.6	93
133	Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. <i>Journal of Viral Hepatitis</i> , 2005, 12, 513-518.	1.0	23
134	Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 841-849.	1.9	25
135	Comparison of the COBAS TaqMan [®] , [†] HBV test with the COBAS Amplicor monitor [®] , [‡] test for measurement of hepatitis B virus DNA in serum. <i>Journal of Medical Virology</i> , 2005, 77, 486-490.	2.5	16
136	Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. <i>Gut</i> , 2005, 54, 1610-1614.	6.1	317
137	Determinants for the Occurrence of Acute Exacerbation of Hepatitis B Virus Infection in Chinese Patients after HBeAg Seroclearance. <i>Journal of Clinical Microbiology</i> , 2005, 43, 1594-1599.	1.8	6
138	Effect of Lamivudine Therapy on the Serum Covalently Closed-Circular (ccc) DNA of Chronic Hepatitis B Infection. <i>American Journal of Gastroenterology</i> , 2005, 100, 1099-1103.	0.2	39
139	Detection of Intrahepatic Hepatitis B Virus DNA and Correlation with Hepatic Necroinflammation and Fibrosis. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3920-3924.	1.8	21
140	Real-Time PCR Assay Using Molecular Beacon for Quantitation of Hepatitis B Virus DNA. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3438-3440.	1.8	35
141	Clinical Evaluation of the Digene Hybrid Capture II Test and the COBAS AMPLICOR Monitor Test for Determination of Hepatitis B Virus DNA Levels. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3513-3517.	1.8	12
142	Long-Term Follow-Up Study of Chinese Patients with YMDD Mutations: Significance of Hepatitis B Virus Genotypes and Characteristics of Biochemical Flares. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3932-3936.	1.8	14
143	Longitudinal Study of Hepatitis Activity and Viral Replication before and after HBeAg Seroconversion in Chronic Hepatitis B Patients Infected with Genotypes B and C. <i>Journal of Clinical Microbiology</i> , 2004, 42, 5036-5040.	1.8	34
144	Significance of HBV DNA Levels in Liver Histology of HBeAg and Anti-HBe Positive Patients with Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2004, 99, 2032-2037.	0.2	51

#	ARTICLE	IF	CITATIONS
145	HBsAg Seroclearance in Chinese Patients Receiving Lamivudine Therapy for Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4882-4884.	1.8	22
146	Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. <i>Carcinogenesis</i> , 2004, 25, 1593-1598.	1.3	92
147	HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects. <i>Hepatology</i> , 2004, 39, 1694-1701.	3.6	222
148	Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. <i>Hepatology</i> , 2004, 40, 727-737.	3.6	119
149	18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 941-945.	2.4	94
150	Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. <i>Journal of Hepatology</i> , 2004, 41, 119-125.	1.8	64
151	Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. <i>Hepatology</i> , 2003, 37, 562-567.	3.6	146
152	Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B results of a comparative study in 96 Chinese patients. <i>American Journal of Gastroenterology</i> , 2003, 98, 1181-1185.	0.2	3
153	Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. <i>Journal of Hepatology</i> , 2003, 39, 850-855.	1.8	55
154	Prognostic Factors in Severe Exacerbation of Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2003, 36, 979-984.	2.9	44
155	A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. <i>Gut</i> , 2003, 52, 416-419.	6.1	113
156	Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation. <i>Clinical Infectious Diseases</i> , 2003, 37, 593-597.	2.9	37
157	Hepatitis B Virus Genotypes B and C Do Not Affect the Antiviral Response to Lamivudine. <i>Antiviral Therapy</i> , 2003, 8, 531-534.	0.6	67
158	Relationship between the Development of Precore and Core Promoter Mutations and Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B Virus. <i>Journal of Infectious Diseases</i> , 2002, 186, 1335-1338.	1.9	76
159	Extracellular expression of human epidermal growth factor encoded by an Escherichia coli K-12 plasmid stabilized by the ytl2-incR system of Salmonella typhimurium. <i>Journal of Industrial Microbiology and Biotechnology</i> , 1998, 21, 31-36.	1.4	16